Search

Your search keyword '"Barwad, Adarsh"' showing total 8 results
Start Over Author "Barwad, Adarsh" Journal future science oa
8 results on '"Barwad, Adarsh"'

7. Management and outcomes of advanced hemangioendothelioma at a medical oncology clinic in an Indian tertiary care center.

Author

Tansir G, Rastogi S, Barwad A, Yadav R, Shamim SA, Dhamija E, Pandey R, Garg R, and Shrivastava S

Abstract

Aim: Hemangioendotheliomas (HEs) are malignant vascular tumors with sparse descriptions in literature owing to their rarity., Study Design: Ours is a retrospective study among patients of advanced HEs registered between September 2015 and April 2021., Results: There were 13 patients with median age 34.6 (range: 4-69 years), male preponderance (69%) and predominant subtype of epithelioid HE (76.9%). Common primary sites were viscera (46.2%) and bone (30.8%). Tyrosine kinase inhibitors (TKIs) yielded objective responses in 30% patients whereas chemotherapy only produced disease stabilization in 7.7%., Conclusion: We recognize an aggressive subset of HEs with manifestations such as acute liver failure and splenic rupture. Currently no biomarkers predict the efficacy of TKIs over chemotherapy; however, TKIs showed promising outcomes in this series., (© 2023 Ghazal Tansir & Sameer Rastogi.)

Published
2023
Full Text
View/download PDF

8. Epithelioid sarcoma and its outcome: a retrospective analysis from a tertiary care center in North India.

Author

Kashyap D, Rastogi S, Garg V, Shrivastava S, Barwad A, Shamim SA, Hemrom A, Dhamija E, Bhoriwal S, and Garg R

Abstract

Aim: Clinicopatholgical findings and outcomes in epithelioid sarcoma (ES) patients., Materials & Methods: ES patients registered in sarcoma clinic from 2015 to 2021., Results: There were 20 patients with median age of 26 years. Majority had distal ES (70%) and advanced disease (85%). In patients with advanced disease lymph nodes were involved in 65%, lungs in 58% and others in 35%. Among 14 patients who underwent biopsy outside our institute, nine (64.2 %) had been initially misdiagnosed. Response rates to doxorubicin (n = 12), pazopanib (n = 6), gemcitabine/docetaxel (n = 5), tazemetostat (n = 3) and immunotherapy (n = 2) used in various lines were 16, 16, 20, 33 and 0%, respectively., Conclusion: Our patients had an advanced-stage and distal ES, with a modest response to chemotherapy., (© 2023 Dr Sameer Rastogi.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results